# EDGAR Filing Document

**Accession Number:** 0001178670
**File Stem:** 0001735276-23-000018
**Filing Date:** 2023-2
**Character Count:** 10136
**Document Hash:** 9400ec39e32d988eb418106bc78cb3c0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001735276-23-000018.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001735276-23-000018

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230223

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** PYOTT DAVID E I
- **CENTRAL INDEX KEY:** 0001051578

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36407
- **FILM NUMBER:** 23674963

**MAIL ADDRESS:**
- **STREET 1:** C/O ALLERGAN
- **STREET 2:** 2525 DUPONT DRIVE
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92612
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALNYLAM PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001178670
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770602661
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** (617) 551-8200

**MAIL ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALNYLAM PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020724

## Ex-24

```

LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS

Know all of these presents, that the undersigned hereby
revokes and nullifies any prior power of attorney for Section
16 reporting obligations, and makes, constitutes and appoints
each of Jeffrey Poulton, Indrani Franchini, Andrew Mayer,
Cindy Andrson and Stephen Hall signing singly and each acting
individually,as the undersigneds true and lawful
attorney-in-fact with full power and authority as hereinafter
described to:

(1) execute for and on behalf of the undersigned, in the
Undersigneds capacity as an officer and/or director of Alnylam
Pharmaceuticals, Inc. (the Company), Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section
16(a) of the Securities and Exchange Act of 1934, as amended,
and the rules thereunder (the Exchange Act);

(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to prepare,
complete and execute any such Form 3, 4, or 5, prepare, complete
and execute any amendment or amendments thereto, and timely
deliver and file such form with the United States Security and
Exchange Commission and any stock exchange or similar authority;

(3) seek or obtain, as the undersigneds representative and on
the undersigneds behalf, information regarding transactions in
the Companys securities from any third party, including
brokers, employee benefit plan administrators and trustees, and
the undersigned herby authorizes any such person to release any
such information to such attorney-in-fact and approves and
ratifies any such release of information; and

(4) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-
fact, may be of benefit to, in the interest of, or legally
required by, the undersigned, it being understood that the
documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-facts
discretion.

The undersigned herby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and
thing whatsoever requisite, necessary, or proper to be done in
the exercise of any of the rights and powers herein granted, as
fully to all intents and purposes as to the undersigned might or
could do of personally present, with full power of substitution
or revocation, hereby ratifying and confirming all that such
attorney-in-fact or such attorney-in-facts substitute or
substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-
fact, in serving in such capacity at the request of the
undersigned, are not assuming nor relieving, nor is the Company
assuming nor relieving, any of the undersigneds
responsibilities to comply with Section 16 of the Exchange Act.
The undersigned Acknowledges that neither the company nor the
foregoing attorneys-in-fact assume (i) any liability of the
undersigneds responsibility to comply with the requirements of
the Exchange Act, (ii) any liability of the undersigned for any
failure to comply with such requirements, or (iii) any
obligation or liability of the undersigned for profit
disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4,
and 5 with respect to the undersigneds holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEROF, the undersigned has caused this Power of
Attorney to be executed as of this 6th day of December 2022.

David E.I. Pyott
Print Name

/s/ David E.I. Pyott
Signature

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>PYOTT DAVID E I<br><sub>(Last) (First) (Middle)</sub><br>675 WEST KENDALL STREET<br>HENRI A. TERMEER SQUARE<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02142<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ALNYLAM PHARMACEUTICALS, INC. [ ALNY ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-23 |  | M |  | 136 | A | $0.0 | 136 | D |  |
| Common Stock |  |  |  |  |  |  |  | 27900 | I | by Trust<sup>(1)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(2)</sup> | 2023-02-23 |  | M |  |  | 136 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 136 | $0.0 | 0 | D |  |

---

### Footnotes:

(1) The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.

(2) Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

(3) This award vested on February 23, 2023, the first anniversary of the grant date.

**Signature:** By: /s/ Andrew Mayer, Attorney-in-Fact For: David E.I. Pyott  
**Date:** 2023-02-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**